Introduction
The recent 15% decrease in sample throughput for Personalis's NeXT Personal assay over the past month is a critical issue that demands immediate attention. This analysis will systematically identify, validate, and address the root cause while considering both short-term and long-term implications for the product and company.
To tackle this problem, I'll follow a structured approach that covers issue identification, hypothesis generation, validation, and solution development. My goal is to provide a comprehensive analysis that not only resolves the current throughput issue but also strengthens our overall product performance and reliability.
This analysis follows a structured approach covering issue identification, hypothesis generation, validation, and solution development to address the NeXT Personal assay throughput decrease.
Step 1
Clarifying Questions (3 minutes)
Why it matters: Changes in protocols could directly impact throughput. Expected answer: Yes, we implemented a new quality control step. Impact on approach: If confirmed, we'd focus on optimizing the new process.
Why it matters: Ensures we're addressing a real issue, not a measurement artifact. Expected answer: No changes in calculation methods. Impact on approach: If there were changes, we'd need to reassess our baseline metrics.
Why it matters: Sample variability could affect processing time and success rates. Expected answer: We've started accepting samples from a new clinical partner. Impact on approach: If confirmed, we'd investigate the new sample characteristics and adjust our processes accordingly.
Why it matters: Equipment problems could directly impact throughput. Expected answer: We've had some intermittent issues with one of our sequencers. Impact on approach: If confirmed, we'd prioritize equipment troubleshooting and maintenance.
Practice similar questions
Subscribe to access the full answer